CYTOMX THERAPEUTICS I

CytomX and Regeneron Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer

17 Nov 2022 07:00:00 By Nasdaq GlobeNewswire

CytomX Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

08 Nov 2022 16:10:00 By Nasdaq GlobeNewswire

CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b (CX-801) at the SITC 2022 Annual Meeting

07 Nov 2022 16:15:00 By Nasdaq GlobeNewswire

CytomX Therapeutics to Present at Upcoming November Investor Conferences

02 Nov 2022 16:15:01 By Nasdaq GlobeNewswire

CytomX Therapeutics to Report Third Quarter 2022 Financial Results on November 8, 2022

01 Nov 2022 08:00:01 By Nasdaq GlobeNewswire

CytomX Therapeutics Announces Phase 1 Data Update for anti-CTLA-4 Probody® Therapeutic BMS-986249

12 Sep 2022 08:00:02 By Nasdaq GlobeNewswire

CytomX Therapeutics Presents Overview of Conditionally-Activated Antibody-Drug Conjugate (ADC) Programs Including Next Generation EpCAM-Targeting CX-2051

07 Sep 2022 18:05:00 By Nasdaq GlobeNewswire

CytomX Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

04 Aug 2022 16:15:00 By Nasdaq GlobeNewswire

CytomX Therapeutics to Present at Upcoming Virtual August Investor Conferences

03 Aug 2022 08:00:02 By Nasdaq GlobeNewswire

CytomX Therapeutics to Report Second Quarter 2022 Financial Results on August 4, 2022

28 Jul 2022 08:00:01 By Nasdaq GlobeNewswire

CytomX Therapeutics Provides Strategic Update

13 Jul 2022 16:05:00 By Nasdaq GlobeNewswire

CytomX Therapeutics Announces Phase 2 Results for Praluzatamab Ravtansine in Breast Cancer

06 Jul 2022 16:05:00 By Nasdaq GlobeNewswire

CytomX Therapeutics Announces New Employment Inducement Grants

16 Jun 2022 08:00:01 By Nasdaq GlobeNewswire

CytomX Therapeutics to Present at Jefferies 2022 Global Healthcare Conference

01 Jun 2022 08:00:01 By Nasdaq GlobeNewswire

CytomX Therapeutics Announces First Patient Dosed with CX-904 in Phase 1 Study in Patients with Advanced Solid Tumors

26 May 2022 08:00:00 By Nasdaq GlobeNewswire

CytomX Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

05 May 2022 16:15:00 By Nasdaq GlobeNewswire

CytomX Therapeutics to Report First Quarter 2022 Financial Results on May 5, 2022

28 Apr 2022 08:00:02 By Nasdaq GlobeNewswire

CytomX Therapeutics Announces Retirement of John A. Scarlett, M.D. from Board of Directors

14 Apr 2022 16:15:00 By Nasdaq GlobeNewswire

CytomX Therapeutics Announces Retirement of Frederick W. Gluck from Board of Directors

23 Mar 2022 16:15:00 By Nasdaq GlobeNewswire

CytomX Therapeutics to Present Updated Preclinical Data for Conditionally Activated Cytokine Program at AACR Annual Meeting 2022

17 Mar 2022 08:00:01 By Nasdaq GlobeNewswire